摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(8S,8aS)-8-hydroxy-8-methyl-6(Z)-<2(R)-methylhexylidene>octahydro-5-indolizidinone | 131636-14-1

中文名称
——
中文别名
——
英文名称
(8S,8aS)-8-hydroxy-8-methyl-6(Z)-<2(R)-methylhexylidene>octahydro-5-indolizidinone
英文别名
(3Z)-(5S,6S)-5-hydroxy-3-[(R)-2-methylhexylidene]-5-methylazabicyclo[4.3.0]nonan-2-one;(6Z,8S,8aS)-8-hydroxy-8-methyl-6-[(2R)-2-methylhexylidene]-2,3,7,8a-tetrahydro-1H-indolizin-5-one
(8S,8aS)-8-hydroxy-8-methyl-6(Z)-<2(R)-methylhexylidene>octahydro-5-indolizidinone化学式
CAS
131636-14-1
化学式
C16H27NO2
mdl
——
分子量
265.396
InChiKey
JRHFQXMSFSCEOS-XXVRVBHVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    19
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.81
  • 拓扑面积:
    40.5
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (8S,8aS)-8-hydroxy-8-methyl-6(Z)-<2(R)-methylhexylidene>octahydro-5-indolizidinone 在 lithium aluminium tetrahydride 、 三氯化铝 作用下, 以 乙醚 为溶剂, 以57%的产率得到(+)-Pumiliotoxin 251D
    参考文献:
    名称:
    (+)-Pumiliotoxin 251D 的全合成
    摘要:
    通过将侧链连接到适当功能化的核心吲哚嗪酮衍生物,已经实现了 pumiliotoxins 的会聚全合成。使用醛醇型加成缩合策略,旨在提供环外双键的立体选择性生成,没有给出令人满意的结果。选择的方法是霍纳烯化。最初,反应物核心吲哚里西酮通过酰胺烯醇化物的形成、烯醇磷酸酯的生成和最终的磷酸酯-膦酸酯迁移转化为 α 膦酰胺。酰胺基膦酸酯顺利地经历了霍纳型烯化,以允许在环外双键中成功引入具有高 Z 选择性的侧链。类似地,膦酸酯的引入和随后的烯化可以作为一锅法进行。内酰胺功能的最终还原去除提供了 (-)-8-epi-pumiliotoxin 209 F 和 (+)-pumiliotoxin 251 D。通过 X 射线分析证实了 pumiliotoxin 251 D 的结构。(© Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2002)
    DOI:
    10.1002/1099-0690(200210)2002:19<3315::aid-ejoc3315>3.0.co;2-2
  • 作为产物:
    描述:
    methyl 2-<(S)-N-<(R)-α-methylbenzyl>pyrrolidin-2-yl>propenoate 在 sodium hydroxide 、 sodium tetrahydroborate 、 mercury(II) diacetate乙酸酐二异丁基氢化铝N,N'-二环己基碳二亚胺copper(l) chloridelithium diisopropyl amide三甲基乙酸 作用下, 以 四氢呋喃甲醇甲苯 为溶剂, 反应 32.08h, 生成 (8S,8aS)-8-hydroxy-8-methyl-6(Z)-<2(R)-methylhexylidene>octahydro-5-indolizidinone
    参考文献:
    名称:
    Fox, David N. A.; Lathbury, David; Mahon, Mary F., Journal of the American Chemical Society, 1991, vol. 113, # 7, p. 2652 - 2656
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • FOX, DAVID N. A.;LATHBURY, DAVID;MAHON, MARY F.;MOLLOY, KIERAN C.;GALLAGH+, J. AMER. CHEM. SOC., 113,(1991) N, C. 2652-2656
    作者:FOX, DAVID N. A.、LATHBURY, DAVID、MAHON, MARY F.、MOLLOY, KIERAN C.、GALLAGH+
    DOI:——
    日期:——
  • Total Synthesis of (+)-Pumiliotoxin 251D
    作者:Alexander Sudau、Winfried Münch、Jan-W. Bats、Udo Nubbemeyer
    DOI:10.1002/1099-0690(200210)2002:19<3315::aid-ejoc3315>3.0.co;2-2
    日期:2002.10
    The convergent total synthesis of pumiliotoxins by attachment of the side chain to a suitably functionalized core indolizidinone derivative has been achieved. The use of an aldol-type addition condensation strategy, intended to provide for the stereoselective generation of the exocyclic double bond, gave no satisfactory results. The method of choice was a Horner olefination. Initially, the reactant
    通过将侧链连接到适当功能化的核心吲哚嗪酮衍生物,已经实现了 pumiliotoxins 的会聚全合成。使用醛醇型加成缩合策略,旨在提供环外双键的立体选择性生成,没有给出令人满意的结果。选择的方法是霍纳烯化。最初,反应物核心吲哚里西酮通过酰胺烯醇化物的形成、烯醇磷酸酯的生成和最终的磷酸酯-膦酸酯迁移转化为 α 膦酰胺。酰胺基膦酸酯顺利地经历了霍纳型烯化,以允许在环外双键中成功引入具有高 Z 选择性的侧链。类似地,膦酸酯的引入和随后的烯化可以作为一锅法进行。内酰胺功能的最终还原去除提供了 (-)-8-epi-pumiliotoxin 209 F 和 (+)-pumiliotoxin 251 D。通过 X 射线分析证实了 pumiliotoxin 251 D 的结构。(© Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2002)
  • Fox, David N. A.; Lathbury, David; Mahon, Mary F., Journal of the American Chemical Society, 1991, vol. 113, # 7, p. 2652 - 2656
    作者:Fox, David N. A.、Lathbury, David、Mahon, Mary F.、Molloy, Kieran C.、Gallagher, Timothy
    DOI:——
    日期:——
查看更多

同类化合物

(6E,7R,8R,8aS)-6-[(4E,6S)-6-羟基-2,5-二甲基辛-4-烯-1-亚基]-8-甲基八氢中氮茚-7,8-二醇 pumiliotoxin B pumiliotoxin B (8R,8αS)-8-hydroxy-8-methyl-6-((Z)-2(R)-methyl-hexylidene)octahydroindolizin-7-one erythro pumiliotoxin PTX-B (6Z,8S,8aS)-6-[(2R,4E,6S)-6-(benzyloxy)-2,5-dimethyl-4-octenylidene]-8-{[tert-butyl(dimethyl)silyl]oxy}-8-methyloctahydroindolizine (6Z,8S)-6-[(E,6S)-6-hydroxy-2,5-dimethyloct-4-enylidene]-8-methyl-1,2,3,5,7,8a-hexahydroindolizin-8-ol (8R,8aS,6E)-8-Hydroxy-8-methyl-[(2R,4E,6S)-2,5-dimethyl-6-benzyloxymethyloxy-4-octenylidene]octahydroindolizin-7-done (8R,8aS)-8-hydroxy-6-[(E,2R,6S)-1-hydroxy-2,5-dimethyl-6-(phenylmethoxymethoxy)oct-4-enyl]-8-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-one (+)-Allopumiliotoxin 323B' Pumiliotoxin 237A (1R,2R,9aS)-1-(benzyloxy)-2-hydroxy-3(E)-isobutylidene-1-methyloctahydroquinolizine (7S,8R,8aS)-8-(benzyloxy)-7-hydroxy-8-methyl-6-(E)-<(2R)-2-methylpentylidene>octahydroindolizidine (+)-allopumiliotoxin 267 A (+)-Pumiliotoxin 251D (3E)-(5S,6S)-5-hydroxy-3-[(R)-2-methylhexylidene]-5-methylazabicyclo[4.3.0]nonan-2-one (8S,8aS)-8-hydroxy-8-methyl-6(Z)-<2(R)-methylhexylidene>octahydro-5-indolizidinone (8S,8aS)-8-hydroxy-8-methyl-(6Z)-<(2R,4E,6S)-6-(benzyloxy)-2,5-dimethyl-4-octenylidene>octahydroindolizidine (+)-(15S)-pumiliotoxin A (+)-allopumiliotoxin 339A (6E,7S,8R,8aS)-8-methyl-6-[(E,2R)-2-methyl-5-[(4R,5R)-2,2,5-trimethyl-1,3-dioxolan-4-yl]hex-4-enylidene]-8-phenylmethoxy-1,2,3,5,7,8a-hexahydroindolizin-7-ol (+)-allopumiliotoxin 339 B (7R,8R,8aS)-8-(benzyloxy)-7-hydroxy-6(Z)-<6(R),7(R)-(isopropylidenedioxy)-2(R),5-dimethyl-4(E)-octenylidene>-8-methyloctahydroindolizine (+)-homopumiliotoxin 223G (6Z)-8-methyl-6-(2-methylhexylidene)-1,2,3,5,7,8a-hexahydroindolizine-7,8-diol (7R,8R,8aS,E)-6-((2R,6R,7R,E)-6,7-Dihydroxy-2,5-dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizine-7,8-diol (8S,8aS)-6-[2,2-Dimethyl-hex-(Z)-ylidene]-8-methyl-octahydro-indolizin-8-ol (R,4E,8E)-8-((7R,8R,8aS)-7,8-Dihydroxy-8-methylhexahydroindolizin-6(5H)-ylidene)-4,7-dimethyloct-4-en-3-one (4E,7R,8Z)-8-((1S,9aS)-1-Hydroxy-1-methyltetrahydro-1H-quinolizin-3(2H,4H,6H)-ylidene)-4,7-dimethyloct-4-ene-2,3-diol (1S,9aS,Z)-3-((2R,E)-7-Hydroxy-2,5-dimethyloct-4-en-1-ylidene)-1-methyloctahydro-1H-quinolizin-1-ol (1S,9aS,Z)-3-((2R,E)-6-Hydroxy-2,5-dimethylnon-4-en-1-ylidene)-1-methyloctahydro-1H-quinolizin-1-ol (8S,8aS,Z)-6-((R,4E,6E)-2,5-Dimethylocta-4,6-dien-1-ylidene)-8-methyloctahydroindolizin-8-ol (8S,Z)-6-((2R,E)-6-Hydroxy-2,5-dimethylhept-4-en-1-ylidene)-8-methyloctahydroindolizin-8-ol (R,Z)-6-((8S,8aS)-8-Hydroxy-8-methylhexahydroindolizin-6(5H)-ylidene)-5-methylhexan-2-one (8S,8aS,Z)-6-((2R)-4-Hydroxy-2-methylpentylidene)-8-methyloctahydroindolizin-8-ol (1S,9aS,Z)-3-((S)-3-Hydroxy-2-methylpropylidene)-1-methyloctahydro-1H-quinolizin-1-ol (8S,8aS,Z)-8-Methyl-6-((R)-2-methylpentylidene)octahydroindolizin-8-ol (6E)-8-methyl-6-(2-methylhexylidene)-8-phenylmethoxy-1,2,3,5,7,8a-hexahydroindolizin-7-ol (6Z)-6-[(E)-6-hydroxy-2,5-dimethyloct-4-enylidene]-8-methyl-1,2,3,5,7,8a-hexahydroindolizin-8-ol (8S,8aS,Z)-6-((2R)-5-Hydroxy-2-methylhexylidene)-8-methyloctahydroindolizin-8-ol Allopumiliotoxin 253a (8R,8aS,E)-6-((2R,6R,E)-6-Hydroxy-2,5-dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizine-7,8-diol Pumiliotoxin 309a (6E)-8-methyl-6-(2-methylhexylidene)-1,2,3,5,7,8a-hexahydroindolizine-7,8-diol (+)-Pumiliotoxin B 8-Methyl-6-(2-methylhexylidene)-8-phenylmethoxy-1,2,3,5,7,8a-hexahydroindolizin-7-ol (1S,9aS,Z)-3-((2R)-6-Hydroxy-2,5-dimethyloctylidene)-1-methyloctahydro-1H-quinolizin-1-ol (8S,8aS,Z)-6-((R)-7-Hydroxy-2-methylheptylidene)-8-methyloctahydroindolizin-8-ol (8S,8aS,Z)-6-((R,E)-2,5-Dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizin-8-ol (8S,8aS,Z)-8-Methyl-6-((R,E)-2-methyl-5-((4R,5S)-2,2,5-trimethyl-1,3,2-dioxasilolan-4-yl)hex-4-en-1-ylidene)octahydroindolizin-8-ol